Glaukos Corporation (NYSE: GKOS) shares traded at USD 86.96 with a daily change of -0.45 or -0.51%. The company operates in the medical devices sector and has a market capitalization of approximately USD 4.99 billion. This update provides investors with a detailed review of the company’s profile, recent stock movements, and trading specifics.
Company Overview
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company headquartered in San Clemente, California. Founded in 1998, it develops novel therapies for treating glaucoma, corneal disorders, and retinal diseases. Its leading products include the iStent and iStent inject series, designed to improve aqueous humor outflow during cataract surgery for patients with mild to moderate open-angle glaucoma.
The company has advanced projects in its pipeline, notably the iStent Infinite—a triple stent device for refractory glaucoma—and the iDose TR, which uses an implantable platform to deliver consistent medication. Glaukos markets its products through direct sales channels and international distributors.
Stock Performance
On the latest trading day, GKOS closed at USD 86.96, representing a drop of 0.45 points. This is a -0.51% change from the previous close. The stock is currently trading nearer to the lower part of its 52-week range of USD 77.102 to USD 163.71, indicating significant volatility over the past year.
Trading volume reached 317,357 shares, which is below the average volume of 933,512 shares, suggesting moderate investor activity. A lower volume compared to the average may indicate reduced short-term trading interest or investor caution following prior fluctuation.
Market Position and Sector
Glaukos operates in the healthcare sector with a focus on medical devices for ophthalmology. The company is positioned among specialized device manufacturers, catering to both surgical and pharmaceutical treatment needs. Its innovative solutions enable it to compete effectively in the United States and international markets.
Long-term demand for glaucoma treatments is influenced by aging populations and increasing prevalence of ocular diseases. This supports Glaukos’ market relevance, particularly given its research investment and product diversification strategy.
Governance and Leadership
Thomas William Burns serves as Chief Executive Officer. His leadership has overseen the expansion of both the device portfolio and pharmaceutical pipeline, enabling strategic positioning in niche ophthalmic solutions. Under current governance, Glaukos continues to align R&D efforts with clinical needs, aiming for regulatory approvals and market adoption.
The company maintains a workforce of 995 full-time employees, reflecting its scale in both manufacturing and distribution.
Key Financial Data
Key indicators for Glaukos include:
- Price: USD 86.96 per share
- Market Capitalization: USD 4,987,154,870
- Dividend: None (last dividend: 0)
- 52-Week Range: USD 77.102 to USD 163.71
- Average Volume: 933,512 shares
- Current Volume: 317,357 shares
The absence of dividends may appeal to investors focusing on growth rather than income. Market cap near USD 5 billion places the firm in mid-cap territory, often characterized by growth potential with moderate risk. The significant range between high and low prices indicates opportunities for gains but also inherent volatility.
FAQ
- Does Glaukos Corporation pay dividends?
No. The last recorded dividend was 0, indicating the company does not currently provide shareholder payouts. - Where is the stock listed?
Glaukos is traded on the New York Stock Exchange under the symbol GKOS. - What is the company’s ISIN and CUSIP?
ISIN: US3773221029, CUSIP: 377322102. - How many employees does Glaukos have?
995 full-time staff support operations globally. - Who is the CEO?
Thomas William Burns leads the company.
Conclusion
Glaukos Corporation shows specialized strength in ophthalmic medical devices with an active development pipeline. Current trading reflects mild downward movement and subdued volume. For investors, the stock presents a mid-cap growth opportunity with sector-specific risks tied to regulatory clearance and competition.
Disclaimer
This article is for informational purposes only. It does not constitute investment advice. Investors should conduct their own research before making financial decisions.
Announcement
For full information about the company, see the link below.